Abstract
The efficacy of protracted schedules of therapy of the topoisomerase I inhibitors 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) and 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (irinotecan; CPT-11) were evaluated against a panel of 21 human tumor xenografts derived from adult and pediatric malignancies. Tumors included eight colon adenocarcinomas, representing an intrinsically chemorefractory malignancy, six lines derived from childhood rhabdomyosarcoma (three embryonal, three alveolar) representing a chemoresponsive histiotype, sublines of rhabdomyosarcomas selected in vivo for resistance to vincristine and melphalan, and three pediatric brain tmors. All tumors were grown at the subcutaneous site. Topotecan was administered by oral gavage 5 days per week for 12 consecutive weeks. The maximum tolerated dose (MTD) was 1.5 mg/kg per dose. Irinotecan was given by i.v. administration daily for 5 days each week for 2 weeks [(d×5)2] (one cycle of therapy), repeated every 21 days. The MTD for three cycles was 10 mg/kg per dose. Treatment was started against advanced tumors. Topotecan caused a high frequency of objective regressions in one of eight colon tumor lines, whereas irinotecan caused complete regressions (CR) of all tumors in three colon lines and a high frequency of CRs in three additional lines. Both drugs demonstrated similar activity against rhabdomyosarcoma xenografts. Topotecan caused CR of all tumors in four of six lines, and irinotecan in five of six lines evaluated. Both agents retained full activity against tumors selected for primary resistance to vincristine, but only irinotecan retained activity against a tumor selected for primary resistance to melphalan. Both agents demonstrated good activity against brain tumor xenografts with irinotecan causing CR in two of three lines and topotecan inducing CR in one of three lines. Results indicate that low-dose protracted schedules of daily administration of these topoisomerase I inhibitors is either equi-effective or more efficacious than more intense shorter schedules of administration reported previously.
Similar content being viewed by others
References
Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665
Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1990) Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98
Gottlieb JA, Luce J (1972) Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103
Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54: 461
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95
Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Pomesil M (1989) DNA topoisomerase 1-targeted chemotherapy of human colon cancer xenografts. Science 246: 1046
Pantazis P, Hinz HR, Mendoza JT, Kozielski AS, Williams LJ, Stehlin JS Jr, Giovanella BC (1992) Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980
Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31: 229
Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD (1994) Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171
Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944
Matsuzaki T, Yokokura T, Mutai M, Tsuruo T (1988) Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308
Bissery MC, Mathieu-Boué A, Lavelle F (1991) Preclinical evaluation of CPT-11, a camptothecin derivative. Proc Am Assoc Cancer Res 33: A2389
Bissery MC, Mathieu-Boué A, Lavelle F (1992) Experimental activity of CPT-11 in vitro and in vivo. Ann Oncol 3 [Suppl 1]: A093
Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K (1991) Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192
Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boué, A, Houghton JA (1993) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase inhibitor 9-dimethylaminomethyl-10-hydoxycamptothecin Cancer Res 53: 2823
Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T (1988) Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71
Taguchi T, Wakui A, Hasegawa K (1990) Phase I clinical study of CPT-11. Gan To KagakuRyoho 17: 115
Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225
Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907
Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16
Masuda N, Fukuoka M, Kudoh, S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanoi M, Nitta T, et al (1993) Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68: 777
Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T, et al (1994) Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12: 90
Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio M, Karato A, et al (1994) Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose vindesine in advanced non-small cell lung cancer. Cancer Res 54: 2636
Shimada Y, Sasaki Y, Sugano K, Shirao K, Kondo H, Yokota T, Saito D, Tamura T, Ohe Y, Shinaki T, et al (1993) Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc Am Assoc Clin Oncol 12: A575
Negoro S, Fukuoka M, Masuda N, Kusunoki Y, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Hirashima T, Tamanoi M, et al (1993) Phase I study of irinotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer. Proc Am Assoc Clin Oncol 12: A331
Houghton PJ, Houghton JA, Myers L, Cheshire PJ, Howbert JJ, Grindey GB (1989) Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol 25: 84
Houghton JA, Houghton PJ, Webber BL (1982) Growth and characterization of childhood rhabdomyosarcomas as xenografts. J Natl Cancer Inst 68: 437
Houghton JA, Houghton PJ, Hazelton BJ, Douglass EC (1985) In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res 45: 2706
Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H, Houghton PJ (1987) Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res 47: 4501
Douglass EC, Valentine M, Etcubanas E, Parham DM, Webber BC, Houghton JA, Houghton PJ, Green AA (1987) A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 45: 148
Houghton JA, Cook RL, Lutz PJ, Houghton PJ (1984) Childhood rhabdomyosarcoma xenografts: response to DNA interacting agents and agents used in current clinical therapy. Eur J Cancer Clin Oncol 20:955
Houghton JA, Cook RL, Lutz PJ, Houghton PJ (1985) Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 69: 91
Horton JK, Houghton PJ, Houghton JA (1987) Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard. Cancer Res 47: 6288
Houghton JA, Taylor DM (1978) Growth characteristics of human colorectal tumors during serial passage in immune-deprived mice. Br J Cancer 37: 213
Houghton JA, Taylor DM (1978) Maintenance of biological and biochemical characteristics of human colorectal tumors during serial passage in immune-deprived mice. Br J Cancer 37: 199
Houghton JA, Houghton PJ (1987) The suitability and use of human tumor xenografts. In: Kallman RF (ed) Rodent tumor models in experimental cancer therapy. Pergamen Press, New York, p 199
Houghton JA, Houghton PJ (1980) On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice. Cancer 45: 1159
Houghton PJ, Horton JK, Houghton JA (1991) Drug sensitivity and resistance in the xenograft model. In: Maurer HM, Ruyman FB, Pochedly C (eds) Rhabdomyosarcomas and related tumors in children and adolescents. CRC Press, Boston, p 188
Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC Jr, Jacobsen PF, Mulbaier LH, Bigner DD (1988) Experimental chemotherapy of human medulloblastom cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48: 4189
Del-Bino GD, Lassota P, Darzynkiewicz Z (1991) The s-phase cytotoxicity of comptothecin. Exp Cell Res 193: 27
Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia D (1994) Irinotecan (CPT-11) high dose escalation with intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446
Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucoronidation with diarrhea. Cancer Res 54: 3723
DeMorais SMF, Wells PG (1989) Enhanced acetominophen toxicity in rats with bilirubin glucoronyl transferase deficiency. Hepatology 10: 163
Hjelle JJ (1986) Hepatic UDP-glucoronic acid regulation during acetominophen biotransformation in rats. J Pharmacol Exp Ther 237: 750
Author information
Authors and Affiliations
Additional information
Supported in part by PHS awards CA32613, CA23099, CA60178, NS30245, Cancer Center Support CORE Grant CA21765, American Cancer Society grant DHR 67E, and by American Lebanese Syrian Associated Charities (ALSAC).
Rights and permissions
About this article
Cite this article
Houghton, P.J., Cheshire, P.J., Hallman, J.D. et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36, 393–403 (1995). https://doi.org/10.1007/BF00686188
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686188